These

chemokine changes were abolished when TNF-α receptor was neutralized by Etanercept. To dissect the role of PMN in this context, we pretreated rats with Repertaxin (Rep), a small molecule inhibitor of CXCR1 and CXCR2, to block recruitment and activation of PMN by CXCL1 or CXCL2 after cell transplantation. In Rep-treated rats, transplanted cell numbers increased at most by 2-fold, which was less than after Thal, p<0.001. Finally, learn more we tested cell priming before transplantation with Thal plus or minus bosentan to block endothelin-1 A/B receptors. Liver repopulation increased in retrorsine/PH-conditioned rats after bosentan-primed but not after Thal-primed cells, p<0.05. Conclusions: Transplanted cell engraftment and liver repopulation benefited from Thal pre-treatment independently of PMN or KC-mediated inflammation. The synergism with ET1 receptor blockade and Thal indicates this combined drug approach will advance cell therapy applications. Disclosures: The following people have nothing to disclose: Preeti Viswanathan, Sorabh Kapoor, Brigid Joseph, Ekaterine Berishvili, Sanjeev Gupta Introduction: The inflammasome plays a crucial role in the pathogenesis of NASH and alcoholic hepatitis, and HIF1 α is

required for sustained inflammasome activity. Digoxin was identified with potent HIF1 α antagonist but its role in liver disease is unexamined. Aim: Ruxolitinib manufacturer To assess whether a low dose of digoxin has therapeutic effects in NASH and alcoholic hepatitis in mice, and investigate the molecular mechanisms. Methods: C57BL/6J male mice were placed on a 45% high fat diet (HFD) for 11weeks with and without digoxin (ip 1mg/kg twice a week). Digoxin 1mg/kg ip daily in mice results in the therapeutic serum levels achieved in humans (0.5-2 ng/ml). Plasma ALT, liver histology, neutrophil staining, leukocytes profiling, mitochondrial reactive oxygen species (ROS) generation, and gene transcriptome microarrays were

analyzed. The ability of digoxin to inhibit inflammasome in mouse and human macro-phages was tested. The chronic plus binge model of alcoholic hepatitis and LPS/D-GalN hepatitis models were also performed. Results: In all three models digoxin resulted in reduced histological injury, neutrophilic infiltrate and lower serum ALT’s (417 +/− 398 U/L in HFD vs 91 +/− 73 Depsipeptide price U/L in HFD+DIG, P< 0.001). Starting digoxin after 4 weeks HFD still showed significant reduction in liver inflammation (neutrophil 24.6% in HFD vs 14.3% in HFD+DIG; monocytes 31.6% in HFD vs 19.1% in HFD+DIG) without a reduction in food intake. In LPS/D-GalN hepatitis a dose titration of twice, a quarter and a twentieth of the human equivalent dose resulted in improvement of liver hemorrhage and necrosis, reduction in liver HIF-1 α and Pro-IL-1 β transcripts as well as the proteins of IL-1 β, HIF-1 α, pro-IL-1 β and cleaved (P10) caspase-1.